|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000181291 |
Summary for TMEM132E |
Gene summary |
| Gene information | Ensembl ID | ENSG00000181291 | Gene symbol | TMEM132E |
| Gene name | transmembrane protein 132E | |
| HGNC | 26991 | |
| Entrez ID | 124842 | |
| Gene type | protein_coding | |
| Synonyms | TMEM132E|DFNB99 | |
| UniProtAcc | Q6IEE7 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for TMEM132E |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for TMEM132E |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for TMEM132E |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg21745612 | chr17:34580617 | CGI:chr17:34578946-34581852 | promoter | 1.63e-01 | 3.37e-01 | -2.24e+00 | 2.49e-02 | 3.80e-02 | -1.73e-01 |
| BRCA | cg03442425 | chr17:34580620 | CGI:chr17:34578946-34581852 | promoter | 2.15e-01 | 4.18e-01 | -2.51e+00 | 1.20e-02 | 2.86e-02 | -2.03e-01 |
| BRCA | cg08033114 | chr17:34580900 | CGI:chr17:34578946-34581852 | UTR,promoter,exon,gene body | 1.39e-01 | 3.15e-01 | -2.28e+00 | 2.26e-02 | 3.66e-02 | -1.77e-01 |
| BRCA | cg01410878 | chr17:34581266 | CGI:chr17:34578946-34581852 | promoter,gene body | 7.93e-02 | 2.49e-01 | -2.09e+00 | 3.70e-02 | 4.46e-02 | -1.70e-01 |
| BRCA | cg00196787 | chr17:34580113 | CGI:chr17:34578946-34581852 | promoter | 1.30e-01 | 3.32e-01 | -2.78e+00 | 5.38e-03 | 2.10e-02 | -2.02e-01 |
| BRCA | cg06459443 | chr17:34580369 | CGI:chr17:34578946-34581852 | promoter | 6.72e-02 | 2.31e-01 | -3.16e+00 | 1.59e-03 | 1.21e-02 | -1.64e-01 |
| BRCA | cg18338311 | chr17:34580920 | CGI:chr17:34578946-34581852 | UTR,promoter,exon,gene body | 2.30e-01 | 3.97e-01 | -2.07e+00 | 3.84e-02 | 4.52e-02 | -1.66e-01 |
| BRCA | cg17750959 | chr17:34580978 | CGI:chr17:34578946-34581852 | UTR,promoter,exon,gene body | 1.54e-01 | 2.90e-01 | -2.55e+00 | 1.08e-02 | 2.75e-02 | -1.36e-01 |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg21070161 | chr17:34582145 | CGI:chr17:34581988-34582274 | promoter,gene body | 2.56e-01 | 1.25e-01 | 5.24e+00 | 1.58e-07 | 7.39e-07 | 1.32e-01 |
| LUAD | cg04790084 | chr17:34579603 | CGI:chr17:34578946-34581852 | promoter | 1.38e-01 | 1.59e-02 | 3.55e+00 | 3.90e-04 | 8.81e-04 | 1.22e-01 |
| HNSC | cg04790084 | chr17:34579603 | CGI:chr17:34578946-34581852 | promoter | 1.57e-01 | 1.70e-02 | 3.69e+00 | 2.22e-04 | 5.07e-04 | 1.40e-01 |
| HNSC | cg06459443 | chr17:34580369 | CGI:chr17:34578946-34581852 | promoter | 1.60e-01 | 4.81e-02 | 3.84e+00 | 1.24e-04 | 3.11e-04 | 1.12e-01 |
| HNSC | cg18338311 | chr17:34580920 | CGI:chr17:34578946-34581852 | UTR,promoter,exon,gene body | 3.14e-01 | 1.68e-01 | 2.88e+00 | 4.02e-03 | 5.91e-03 | 1.45e-01 |
| LUSC | cg21745612 | chr17:34580617 | CGI:chr17:34578946-34581852 | promoter | 1.55e-01 | 5.28e-02 | 2.39e+00 | 1.69e-02 | 2.09e-02 | 1.03e-01 |
| BLCA | cg21745612 | chr17:34580617 | CGI:chr17:34578946-34581852 | promoter | 3.24e-01 | 7.49e-02 | 3.23e+00 | 1.25e-03 | 2.70e-03 | 2.50e-01 |
| BLCA | cg03442425 | chr17:34580620 | CGI:chr17:34578946-34581852 | promoter | 3.89e-01 | 1.24e-01 | 2.93e+00 | 3.39e-03 | 5.97e-03 | 2.65e-01 |
| BLCA | cg08033114 | chr17:34580900 | CGI:chr17:34578946-34581852 | UTR,promoter,exon,gene body | 2.03e-01 | 6.80e-02 | 2.02e+00 | 4.29e-02 | 4.44e-02 | 1.35e-01 |
| BLCA | cg01410878 | chr17:34581266 | CGI:chr17:34578946-34581852 | promoter,gene body | 2.45e-01 | 3.14e-02 | 2.72e+00 | 6.58e-03 | 1.01e-02 | 2.14e-01 |
| BLCA | cg10451253 | chr17:34580686 | CGI:chr17:34578946-34581852 | promoter | 1.57e-01 | 3.59e-02 | 2.51e+00 | 1.20e-02 | 1.63e-02 | 1.21e-01 |
| BLCA | cg24071532 | chr17:34582023 | CGI:chr17:34581988-34582274 | promoter,gene body | 3.50e-01 | 1.13e-01 | 3.61e+00 | 3.09e-04 | 9.17e-04 | 2.37e-01 |
| BLCA | cg18338311 | chr17:34580920 | CGI:chr17:34578946-34581852 | UTR,promoter,exon,gene body | 2.97e-01 | 1.38e-01 | 2.33e+00 | 1.96e-02 | 2.41e-02 | 1.59e-01 |
| BLCA | cg17750959 | chr17:34580978 | CGI:chr17:34578946-34581852 | UTR,promoter,exon,gene body | 2.83e-01 | 1.44e-01 | 2.21e+00 | 2.70e-02 | 3.10e-02 | 1.39e-01 |
| BLCA | cg21070161 | chr17:34582145 | CGI:chr17:34581988-34582274 | promoter,gene body | 2.60e-01 | 1.36e-01 | 2.41e+00 | 1.59e-02 | 2.04e-02 | 1.25e-01 |
| KIRP | cg21070161 | chr17:34582145 | CGI:chr17:34581988-34582274 | promoter,gene body | 2.23e-01 | 1.21e-01 | 2.44e+00 | 1.46e-02 | 1.76e-02 | 1.02e-01 |
| CHOL | cg01410878 | chr17:34581266 | CGI:chr17:34578946-34581852 | promoter,gene body | 1.80e-01 | 2.61e-02 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 1.54e-01 |
| CHOL | cg04790084 | chr17:34579603 | CGI:chr17:34578946-34581852 | promoter | 1.85e-01 | 1.87e-02 | 2.43e+00 | 1.50e-02 | 2.65e-02 | 1.66e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg21745612 | chr17:34580617 | CGI:chr17:34578946-34581852 | promoter | 1.63e-01 | 3.55e-02 | 7.59e+00 | 3.18e-14 | 1.09e-13 | 1.28e-01 |
| BRCA | cg03442425 | chr17:34580620 | CGI:chr17:34578946-34581852 | promoter | 2.15e-01 | 5.39e-02 | 8.02e+00 | 1.08e-15 | 4.14e-15 | 1.61e-01 |
| BRCA | cg24071532 | chr17:34582023 | CGI:chr17:34581988-34582274 | promoter,gene body | 3.55e-01 | 1.22e-01 | 1.06e+01 | 2.86e-26 | 2.75e-25 | 2.33e-01 |
| BRCA | cg21070161 | chr17:34582145 | CGI:chr17:34581988-34582274 | promoter,gene body | 3.73e-01 | 1.74e-01 | 9.81e+00 | 9.89e-23 | 6.79e-22 | 1.99e-01 |
| BRCA | cg23753415 | chr17:34582273 | CGI:chr17:34581988-34582274 | promoter,gene body | 2.38e-01 | 1.33e-01 | 6.23e+00 | 4.53e-10 | 1.13e-09 | 1.05e-01 |
| LUAD | cg07660838 | chr17:34582356 | CGI:chr17:34581988-34582274 | promoter,gene body | 2.43e-01 | 1.43e-01 | 3.31e+00 | 9.35e-04 | 3.06e-03 | 1.01e-01 |
| HNSC | cg21070161 | chr17:34582145 | CGI:chr17:34581988-34582274 | promoter,gene body | 2.07e-01 | 1.05e-01 | 2.71e+00 | 6.64e-03 | 1.52e-02 | 1.02e-01 |
| LIHC | cg21745612 | chr17:34580617 | CGI:chr17:34578946-34581852 | promoter | 2.25e-01 | 4.64e-02 | 3.41e+00 | 6.58e-04 | 1.63e-03 | 1.79e-01 |
| LIHC | cg03442425 | chr17:34580620 | CGI:chr17:34578946-34581852 | promoter | 2.70e-01 | 8.64e-02 | 2.97e+00 | 2.94e-03 | 5.28e-03 | 1.84e-01 |
Top |
Exon skipping events with PSI in TCGA for TMEM132E |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Landscape of exon skipping events across multiple cancer types. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for TMEM132E |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for TMEM132E |
TFs related to TMEM132E.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
TMEM132E related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for TMEM132E |
RBPs related to ES in TMEM132E.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
TMEM132E related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs280037 | chr17:33660722:T:C | - | -0.0883094092450961 | 0.0034014021738152 | LGG | Female-baised eQTL |
| rs280049 | chr17:33656876:A:G | - | -0.08762403873118 | 0.0038731973846824 | LGG | Female-baised eQTL |
| rs280051 | chr17:33657483:T:C | - | -0.0873263246948349 | 0.00417637877624609 | LGG | Female-baised eQTL |
| rs190718 | chr17:33659258:A:G | - | -0.0873263246948349 | 0.00417637877624609 | LGG | Female-baised eQTL |
| rs1072783 | chr17:33660157:C:T | - | -0.0856865433261968 | 0.00518939724779724 | LGG | Female-baised eQTL |
| rs646123 | chr17:42568614:G:A | - | 0.083615499096476 | 0.0157460997276647 | LGG | Female-baised eQTL |
| rs645692 | chr17:42549055:C:T | - | 0.0837396515953826 | 0.0162021142817177 | LGG | Female-baised eQTL |
| rs665268 | chr17:42570011:A:G | - | 0.0822846112723469 | 0.020125801524189 | LGG | Female-baised eQTL |
| rs676387 | chr17:42554255:C:A | - | 0.081888270086363 | 0.0220668065422331 | LGG | Female-baised eQTL |
| rs10454087 | chr17:42583623:C:T | - | 0.0809090156450825 | 0.0261194311328101 | LGG | Female-baised eQTL |
| rs12951632 | chr17:42588995:T:C | - | 0.0809090156450825 | 0.0261194311328101 | LGG | Female-baised eQTL |
| rs112666141 | chr17:42601696:G:A | - | 0.0809090156450825 | 0.0261194311328101 | LGG | Female-baised eQTL |
| rs60929812 | chr17:42607430:G:A | - | 0.0809090156450825 | 0.0261194311328101 | LGG | Female-baised eQTL |
| rs192567807 | chr17:42616421:C:T | - | 0.0809090156450825 | 0.0261194311328101 | LGG | Female-baised eQTL |
| rs74322397 | chr17:42616611:C:T | - | 0.0809090156450825 | 0.0261194311328101 | LGG | Female-baised eQTL |
| rs35635959 | chr17:42620270:T:C | - | 0.0809090156450825 | 0.0261194311328101 | LGG | Female-baised eQTL |
| rs12601457 | chr17:42628829:C:T | - | 0.0809090156450825 | 0.0261194311328101 | LGG | Female-baised eQTL |
| rs668799 | chr17:42564217:C:T | - | 0.0810680796997861 | 0.0262692935291415 | LGG | Female-baised eQTL |
| rs12938909 | chr17:42635746:C:G | - | 0.0803815398194589 | 0.0296844887655982 | LGG | Female-baised eQTL |
| rs112581665 | chr17:42637020:C:T | - | 0.0803815398194589 | 0.0296844887655982 | LGG | Female-baised eQTL |
| rs17806303 | chr17:32504610:T:C | - | 0.101832812457821 | 0.0328877588567366 | LGG | Female-baised eQTL |
| rs2292749 | chr17:42666566:C:T | - | 0.0771168234531492 | 0.0414044784899397 | LGG | Female-baised eQTL |
| rs6963 | chr17:42579579:T:A | - | 0.0764852432641203 | 0.0451805699915406 | LGG | Female-baised eQTL |
| rs66918837 | chr17:42647615:G:A | - | 0.0756024678162729 | 0.0476703305401251 | LGG | Female-baised eQTL |
| rs35733365 | chr17:42657766:T:C | - | 0.0756024678162729 | 0.0476703305401251 | LGG | Female-baised eQTL |
| rs11652267 | chr17:43502713:C:T | - | 0.140405925967913 | 0.00853977982714307 | KIRC | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
| Gene ID: ENSG00000181291 | |
| CpG Site: cg24274176 | |
| Position to Gene: gene,exon,CDS | |
| Male Effect: -0.46858045697568 | |
| Female Effect: - |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg24274176 | chr17:34629142 | gene,exon,CDS | -0.46858045697568 | 2.93812792499599e-08 | -0.4327158771363165 | 1.40582434283575e-10 | KIRP |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of TMEM132E |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |